Pennsylvania House Bill HB2162

Pennsylvania 2025-2026 Regular Session

• Introduced: 1/28/26
• Refer: 1/28/26

Caption

Further providing for definitions and for license application.

Summary

HB2162 amends Pennsylvania’s Wholesale Prescription Drug Distributors License Act to broaden and clarify licensing rules for certain drug and medical device businesses. The bill revises the definition of “virtual manufacturer” to include a person with a place of business in Pennsylvania that manufactures and distributes a drug or medical device, does not take physical possession of the product in the Commonwealth, and either holds FDA approval/label code or has already submitted, or plans to submit within 12 months, an FDA application for approval. The bill also adds new license-application requirements for manufacturers of unapproved prescription drugs and for virtual manufacturers of drugs or medical devices that do not yet hold FDA approval or label identification. In both cases, applicants must state that they have submitted an FDA application or intend to do so within 12 months. The Department of Health is prohibited from requiring FDA approval as a condition of licensure under the act, and the bill takes effect 60 days after enactment.

Impact

HB2162 would change the licensing framework for wholesale prescription drug distributors by expanding statutory definitions and limiting the Department of Health’s ability to condition licensure on prior FDA approval. It affects Pennsylvania-based virtual manufacturers, prescription drug manufacturers, and medical device businesses operating under the Wholesale Prescription Drug Distributors License Act, while leaving the broader federal FDA approval process intact.

Sentiment

No committee transcript or vote record is available, so there is no documented floor or committee sentiment to assess. Based on the text, the bill appears generally industry-friendly and pro-innovation, as it creates a pathway for licensing before FDA approval is complete while still requiring disclosure of the applicant’s FDA submission plans.

Contention

The main point of contention is likely the balance between encouraging pharmaceutical and medical device development and maintaining regulatory safeguards. Supporters would favor the bill’s flexibility for emerging manufacturers and virtual manufacturers, while critics may worry that allowing licensure before FDA approval could weaken oversight or create confusion about product readiness and consumer protection. The bill specifically limits the Department of Health’s discretion, which could be a focal point for debate.